Aurobindo Pharma Limited
AUROPHARMA
Clasificación en acciones
#2094
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Precio por acción
$16.95
Capitalización bursátil
$9.75B
Cambio (1 día)
-2.26%
Cambio (1 año)
35.57%
País
IN
Comercio Aurobindo Pharma Limited (AUROPHARMA)
Categoría
Healthcare
Ingresos de Aurobindo Pharma Limited (AUROPHARMA)
Ingresos en Jun 2026 TTM: $3.85B
Según los últimos informes financieros de Aurobindo Pharma Limited, los ingresos actuales de la empresa (TTM) son $3.85B. En 2025, la empresa obtuvo unos ingresos de $3.71B un aumento con respecto a los ingresos del año 2024, que fueron de $3.48B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Aurobindo Pharma Limited desde 2004 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $3.85B | 3.81% |
| 2025 | $3.71B | 6.64% |
| 2024 | $3.48B | 15.00% |
| 2023 | $3.02B | -2.12% |
| 2022 | $3.09B | -8.70% |
| 2021 | $3.38B | 10.38% |
| 2020 | $3.07B | 8.83% |
| 2019 | $2.82B | 11.42% |
| 2018 | $2.53B | 9.80% |
| 2017 | $2.30B | 10.42% |
| 2016 | $2.09B | 7.24% |
| 2015 | $1.94B | -3.94% |
| 2014 | $2.02B | 87.34% |
| 2013 | $1.08B | 20.74% |
| 2012 | $894.99M | -8.97% |
| 2011 | $983.16M | 23.50% |
| 2010 | $796.09M | 31.34% |
| 2009 | $606.15M | -0.42% |
| 2008 | $608.73M | 24.30% |
| 2007 | $489.74M | 36.87% |
| 2006 | $357.80M | 18.22% |
| 2005 | $302.66M | -12.68% |
| 2004 | $346.60M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 71.71% |
IN
|
